2-{4-[(2-Amino-4-oxo-3,4-dihydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid (Folic acid (PteGlu))

ID: ALA1622

Cas Number: 59-30-3

PubChem CID: 135398658

Product Number: F656929, Order Now?

Max Phase: Approved

Molecular Formula: C19H19N7O6

Molecular Weight: 441.40

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Acidum folicum | Folacin | Folate | Foldine | Folettes | Foliamin | Folic acid | Folipac | Incafolic | Millafol | Pteroylglutamic acid | Vitamin b9 | Vitamin bc | Vitamin m | B03BB01 | NSC-3073

Synonyms from Alternative Forms(5): Folic acid sodium salt | Folate sodium | Folic acid, monosodium salt | Sodium folate | Sodium pteroylglutamate

Trade Names(12): Bio science | Folic acid | Folicare | Folicet | Folsan | Folvite | Lexpec | Natur flow | Preconceive | Roche | Vitamin Bc | Vitamin M

Canonical SMILES:  Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1

Standard InChI:  InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1

Standard InChI Key:  OVBPIULPVIDEAO-LBPRGKRZSA-N

Molfile:  

     RDKit          2D

 32 34  0  0  1  0  0  0  0  0999 V2000
    0.7750   -5.7042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9958   -5.7042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3833   -4.6417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3833   -6.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9958   -5.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7750   -5.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6042   -6.0583    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8958   -7.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6042   -4.6458    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5083   -6.7625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7375   -6.7583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1250   -7.1125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2833   -6.7625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2167   -5.7042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3875   -6.7667    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.7417   -8.8833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8958   -7.8250    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.7333   -6.0500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1583   -4.6458    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4458   -5.7042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.1292   -9.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.2167   -4.9958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1250   -7.8208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2792   -6.0542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6667   -7.1208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8333   -6.0583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0583   -6.0583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7375   -8.1750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3500   -7.1125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.3542   -9.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.0542   -6.7667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6667   -5.7000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  4  1  0
  3  6  1  0
  4  1  1  0
  5  3  1  0
  6  1  2  0
  7  2  1  0
  8 13  1  0
  9  5  1  0
 10  8  1  0
 11 12  1  0
 12 10  1  0
 13 24  1  0
 14  7  2  0
 15  4  2  0
 16 28  1  0
 17  8  2  0
 18 11  2  0
 19  6  1  0
 20 26  1  0
 21 16  2  0
 22  9  2  0
 12 23  1  6
 24 32  2  0
 25 31  1  0
 26 14  1  0
 27 20  1  0
 28 23  1  0
 29 11  1  0
 30 16  1  0
 31 27  2  0
 32 27  1  0
  2  5  2  0
 22 14  1  0
 13 25  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA1622

   Folic acid

2. Alternative Forms:

   

   ALA1622

   FOLATE SODIUM

Molecule Features

Natural Product: Yes

Oral: Yes

Chemical Probe: No

Parenteral: Yes

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: Yes

Prodrug: No

Calculated Properties

Molecular Weight: 441.40

Molecular Weight (Monoisotopic): 441.1397

AlogP: -0.04

#Rotatable Bonds: 9

Polar Surface Area: 213.28

Molecular Species: ACID

HBA: 9

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 13

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.32

CX Basic pKa: 2.09

CX LogP: -0.69

CX LogD: -6.93

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.26

Np Likeness Score: -0.40

References

1. Harvison PJ, Kalman TI..  (1992)  Synthesis and biological activity of novel folic acid analogues: pteroyl-S-alkylhomocysteine sulfoximines.,  35  (7): [PMID:1560436] [10.1021/jm00085a010]

2. Ghazala M, Nair MG, Toghiyani TR, Kisliuk RL, Gaumont Y, Kalman TI..  (1986)  Folate analogues. 25. Synthesis and biological evaluation of N10-propargylfolic acid and its reduced derivatives.,  29  (7): [PMID:3100797] [10.1021/jm00157a600]

3. Taira K, Benkovic SJ..  (1988)  Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase.,  31  (1): [PMID:3275776] [10.1021/jm00396a019]

4. Taylor EC, Hamby JM, Shih C, Grindey GB, Rinzel SM, Beardsley GP, Moran RG..  (1989)  Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.,  32  (7): [PMID:2738886] [10.1021/jm00127a019]

5. Patil SA, Shane B, Freisheim JH, Singh SK, Hynes JB..  (1989)  Inhibition of mammalian folylpolyglutamate synthetase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin bearing a terminal L-ornithine.,  32  (7): [PMID:2738891] [10.1021/jm00127a026]

6. Patil SA, Shane B, Freisheim JH, Singh SK, Hynes JB..  (1989)  Inhibition of mammalian folylpolyglutamate synthetase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin bearing a terminal L-ornithine.,  32  (7): [PMID:2738891] [10.1021/jm00127a026]

7. Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH..  (1994)  Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.,  37  (14): [PMID:8035423] [10.1021/jm00040a008]

8. Li SW, Nair MG, Edwards DM, Kisliuk RL, Gaumont Y, Dev IK, Duch DS, Humphreys J, Smith GK, Ferone R..  (1991)  Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid.,  34  (9): [PMID:1895294] [10.1021/jm00113a011]

9. Rosowsky A, Forsch RA, Moran RG..  (1991)  Folic acid analogues lacking the 2-carbon are substrates for folylpolyglutamate synthetase and inhibit cell growth.,  34  (1): [PMID:1992148] [10.1021/jm00105a070]

10. Brixner DI, Ueda T, Cheng YC, Hynes JB, Broom AD..  (1987)  Folate analogues as inhibitors of thymidylate synthase.,  30  (4): [PMID:3470522] [10.1021/jm00387a016]

11. Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, Moran RG..  (1985)  Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.,  28  (7): [PMID:4009615] [10.1021/jm00145a012]

12. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR..  (2005)  Targeting and inhibition of cell growth by an engineered dendritic nanodevice.,  48  (11): [PMID:15916424] [10.1021/jm040187v]

13. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P..  (2008)  Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,  51  (19): [PMID:18788725] [10.1021/jm8003152]

14. Tomasić T, Zidar N, Rupnik V, Kovac A, Blanot D, Gobec S, Kikelj D, Masic LP..  (2009)  Synthesis and biological evaluation of new glutamic acid-based inhibitors of MurD ligase.,  19  (1): [PMID:19014883] [10.1016/j.bmcl.2008.10.129]

15. Kwon YK, Lu W, Melamud E, Khanam N, Bognar A, Rabinowitz JD..  (2008)  A domino effect in antifolate drug action in Escherichia coli.,  4  (10): [PMID:18724364] [10.1038/nchembio.108]

16. PubChem BioAssay data set, 

17. PubChem BioAssay data set, 

18. PubChem BioAssay data set, 

19. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ..  (2010)  Developing structure-activity relationships for the prediction of hepatotoxicity.,  23  (7): [PMID:20553011] [10.1021/tx1000865]

20. Ekins S, Williams AJ, Xu JJ..  (2010)  A predictive ligand-based Bayesian model for human drug-induced liver injury.,  38  (12): [PMID:20843939] [10.1124/dmd.110.035113]

21. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

22. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF..  (2008)  Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.,  18  (2): [PMID:20020916] [10.1080/15376510701857262]

23. Unpublished dataset, 

24. Toropov AA, Toropova AP, Raska I..  (2008)  QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.,  43  (4): [PMID:17629592] [10.1016/j.ejmech.2007.05.007]

25. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W..  (2011)  FDA-approved drug labeling for the study of drug-induced liver injury.,  16  (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007]

26. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

27. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD..  (2001)  Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.,  61  (1): [PMID:11585759]

28. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD..  (2002)  Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.,  62  (1): [PMID:12036927]

29. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D..  (2003)  Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.,  38  (1): [PMID:12883481] [10.1053/jhep.2003.50331]

30. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K..  (1998)  Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney.,  438  (1): [PMID:9827570] [10.1016/s0014-5793(98)01328-3]

31. Masuda S, Ibaramoto K, Takeuchi A, Saito H, Hashimoto Y, Inui KI..  (1999)  Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.,  55  (1): [PMID:10101033]

32. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD..  (2003)  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.,  63  (1): [PMID:12874005]

33. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD..  (2004)  Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).,  67  (1): [PMID:15537867] [10.1124/mol.104.007138]

34. Saito H, Masuda S, Inui K..  (1996)  Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney.,  271  (1): [PMID:8702823] [10.1074/jbc.271.34.20719]

35. Takeuchi A, Masuda S, Saito H, Hashimoto Y, Inui K..  (2000)  Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1.,  293  (1): [PMID:10869408]

36. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G..  (1999)  Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.,  274  (1): [PMID:9880528] [10.1074/jbc.274.3.1519]

37. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

38. Pushpalatha HG, Mythrashree SR, Shetty R, Geetha NP, Sharathchandra RG, Amruthesh KN, Shetty HS..  (2007)  Ability of vitamins to induce downy mildew disease resistance and growth promotion in pearl millet,  26  (11): [10.1016/j.cropro.2007.02.012]

39. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP..  (2013)  Structure-based identification of OATP1B1/3 inhibitors.,  83  (6): [PMID:23571415] [10.1124/mol.112.084152]

40. Wang Y, Cherian C, Orr S, Mitchell-Ryan S, Hou Z, Raghavan S, Matherly LH, Gangjee A..  (2013)  Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.,  56  (21): [PMID:24111942] [10.1021/jm401139z]

41. Ke MR, Yeung SL, Ng DK, Fong WP, Lo PC..  (2013)  Preparation and in vitro photodynamic activities of folate-conjugated distyryl boron dipyrromethene based photosensitizers.,  56  (21): [PMID:24088087] [10.1021/jm4009168]

42. PubChem BioAssay data set, 

43. PubChem BioAssay data set, 

44. PubChem BioAssay data set, 

45. Seydel JK, Butte W..  (1977)  P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).,  20  (3): [PMID:321779] [10.1021/jm00213a023]

46. Golani LK, George C, Zhao S, Raghavan S, Orr S, Wallace A, Wilson MR, Hou Z, Matherly LH, Gangjee A..  (2014)  Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.,  57  (19): [PMID:25234128] [10.1021/jm501113m]

47. WHO Anatomical Therapeutic Chemical Classification, 

48. British National Formulary (72nd edition), 

49. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y..  (2014)  Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.,  60  (3): [PMID:24799086] [10.1002/hep.27206]

50. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T..  (2012)  Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.,  40  (12): [PMID:22961681] [10.1124/dmd.112.047068]

51. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

52. Unpublished dataset, 

53. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

54. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

55. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

56. Zhuang C, Guan X, Ma H, Cong H, Zhang W, Miao Z..  (2019)  Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment.,  163  [PMID:30580240] [10.1016/j.ejmech.2018.12.035]

57.  (2016)  Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity, 

58. Geersing A, de Vries RH, Jansen G, Rots MG, Roelfes G..  (2019)  Folic acid conjugates of a bleomycin mimic for selective targeting of folate receptor positive cancer cells.,  29  (15): [PMID:31155430] [10.1016/j.bmcl.2019.05.047]

59. Rana P, Will Y, Nadanaciva S, Jones LH..  (2016)  Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.,  26  (16): [PMID:27397500] [10.1016/j.bmcl.2016.06.088]

60. Wang Y, Hilty C..  (2019)  Determination of Ligand Binding Epitope Structures Using Polarization Transfer from Hyperpolarized Ligands.,  62  (5): [PMID:30715877] [10.1021/acs.jmedchem.8b01711]

61. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

62. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

63. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection,  [10.6019/CHEMBL4513141]

64. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

65. Saito R,Suzuki S,Sasaki K.  (2016)  Pterin-7-carboxamides as a new class of aldose reductase inhibitors.,  26  (20.0): [PMID:27666634] [10.1016/j.bmcl.2016.09.033]

66. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

67. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(13):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• TP-search Transporter Database
• Patent Bioactivity Data
• CO-ADD antimicrobial screening data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data
• Fraunhofer HDAC6